Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28974948 | 0.87 | SCN5A (0.37) | ADRB2ADRB1ESR1ESR2XDH | |
| SCHEMBL1083387 | 0.82 | ADRB2 (0.61) | ADRB2ADRB1ESR1XDHFOS | |
| SCHEMBL15553330 | 0.82 | NQO1 (0.50) | ESR1ESR2BACE1LMNA | |
| SCHEMBL19121047 | 0.81 | ALDH1A1 (0.41) | XDHFOSJUNLMNAMAOA | |
| SCHEMBL28221888 | 0.80 | ADRB2 (0.47) | ADRB2ADRB1XDHLMNAMAOB | |
| SCHEMBL25328657 | 0.80 | GABRA1 (0.39) | XDHFOSJUNPDK2 | |
| SCHEMBL19440429 | 0.79 | LMNA (0.40) | XDHBACE1FOSJUNLMNA | |
| SCHEMBL21327850 | 0.79 | NR1H4 (0.47) | XDHFOSJUN | |
| SCHEMBL3720155 | 0.79 | ADRB2 (0.46) | ADRB2ADRB1ESR1ESR2XDH | |
| SCHEMBL25329497 | 0.79 | ESR1 (0.53) | ADRB2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | ADRB2 4700/4885ADRB1 4646/4885ESR1 3959/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | ADRB2 1644/4885ADRB1 1076/4885ESR1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.